Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
26,341 people get JNJ articles and Market Currents by email alert.
Get email alerts on JNJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
The Ulcerative Colitis Game Of ThronesCory Renauer • Tue, May 21 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
The Ulcerative Colitis Game Of ThronesCory Renauer • Tue, May 21
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Johnson & Johnson's CEO Hosts Annual Meeting of Shareholders (Transcript)Thu, Apr 26, 2012 • 1 Comment
-
Johnson & Johnson Services, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Johnson & Johnson Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Johnson & Johnson Q4 2009 Earnings Call TranscriptTue, Jan 26, 2010
-
Johnson & Johnson Q3 2009 Earnings Call TranscriptTue, Oct 13, 2009
-
Johnson & Johnson Q2 2009 Earnings Call TranscriptTue, Jul 14, 2009
-
Johnson & Johnson F1Q09 (Qtr End 03/29/09) Earnings Call TranscriptTue, Apr 14, 2009 • 1 Comment
-
Johnson & Johnson Q4 2008 Earnings Call TranscriptTue, Jan 20, 2009
-
at CNBC.com (Fri, 1:43PM)
-
at CNBC.com (Fri, 11:27AM)
-
at MarketWatch.com (Fri, 7:00AM)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 14, 2013)
-
at MarketWatch.com (May 12, 2013)
-
at MarketWatch.com (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
JNJ vs. ETF Alternatives
Company Description
General
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 15, 2012, 1:50 PM Johnson & Johnson's (JNJ +0.5%) subsidiary Alza Corp. and Janssen Pharmaceutica NV agree to transfer world-wide rights for the premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals (FURX +9.3%). Comment! [Healthcare, Global & FX, On the Move]
- Wednesday, May 9, 2012, 11:34 AM J&J (JNJ) adds another approval request to the FDA for Xarelto, applying to use the blood thinner for helping to reduce the risk of blood clots developing in heart stents in patients with acute coronary syndrome. Xarelto is already authorized for certain use cases. Comment! [Healthcare]
- Tuesday, May 1, 2012, 11:49 AM New J&J (JNJ) CEO Alex Gorsky is looking to strengthen the company's medical-device unit via takeovers, he tells Bloomberg in an interview. "We remain committed to cardiovascular," Gorsky says, despite sales shrinking 44% since 2006. On the analyst wish list are Edwards Lifesciences (EW) and St. Jude Medical (STJ). 2 Comments [Healthcare]
- Monday, April 30, 2012, 5:20 AM Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees. Comment! [Healthcare, Quick Ideas]
- Thursday, April 26, 2012, 10:58 AM Johnson & Johnson (JNJ +0.4%) announces at its annual shareholders meeting a 7.0% increase in its quarterly dividend rate, from $0.57 per share to $0.61 per share. 5 Comments [Healthcare]
- Thursday, April 19, 2012, 5:12 AM The EU approves Johnson & Johnson's (JNJ) $21.3B purchase of Swiss medical device maker Synthes after J&J pledged to divest its trauma operations in the region. "We obtained remedies to ensure that competition will remain strong in these markets," EU Competition Commissioner Joaquin Almunia says. Comment! [M&A, Healthcare]
- Tuesday, April 17, 2012, 8:12 AM More on Johnson & Johnson's (JNJ) Q1: Worldwide Consumer sales -2.4% Y/Y to $3.6B, hurt by negative currency impact of 2.9%. Worldwide pharmaceutical sales +1.2% to $6.1B, led by strong international sales of Remicade. Worldwide Medical Devices and Diagnostics sales -0.3% to $6.4B. Sees FY12 EPS of $5.07-$5.17, above prior guidance of $5.05-$5.15. Shares +0.5% premarket. (PR) 1 Comment [Earnings, On the Move]
- Tuesday, April 17, 2012, 7:47 AM Johnson & Johnson (JNJ): Q1 EPS of $1.41 beats by $0.07. Revenue of $16.1B (flat Y/Y) misses by $125M. Shares +0.6% premarket. (PR) 2 Comments [Earnings, Consumer]
- Tuesday, April 17, 2012, 12:05 AM Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, GWW, JNJ, KO, NTRS, OMC, STT, USB, USG Comment! [Earnings]
- Monday, April 16, 2012, 5:30 PM Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, GWW, JNJ, KO, NTRS, OMC, STT, USB, USG Comment! [Earnings]
- Monday, April 16, 2012, 5:25 PM The Street is underestimating Johnson & Johnson (JNJ), Citi's Matthew Dodds maintains, and shares could pop if sales exceed estimates when it reports its Q1 tomorrow morning: "All three of JNJ’s divisions are expected to see accelerating sales growth as we move through 2012, with a notable jump set for Q3 when generic pharma comparisons ease." Comment! [Healthcare]
- Wednesday, April 11, 2012, 11:10 AM The judge in an Arkansas case against Johnson & Johnson (JNJ -0.5%) tags the firm with a $1.1B penalty after it was found guilty of deception over the marketing of antipyschotic drug Risperdal. Shares of JNJ are snoozing the news with the verdict and obligatory appeal already anticipated. 4 Comments [Consumer]
- Wednesday, April 11, 2012, 8:57 AM Johnson & Johnson (JNJ) could face a massive fine after an Arkansas jury yesterday found the company and its Janssen unit guilty of engaging in "false or deceptive acts" about the risks of the antipsychotic drug Risperdal, and of breaking consumer laws. It's not the first case J&J has lost over Risperdal. Arkansas is seeking $1.25B in fines. (previous) Comment! [Healthcare]
- Wednesday, April 4, 2012, 2:48 PM General Mills (GIS) is the most reputable company in America, according to a study (.pdf) of U.S. consumers conducted by the Reputation Institute. General Mills unseated former top finisher Amazon (AMZN), which fell to #5. KFT, JNJ, and K round out the top 5. AIG and XOM saw major improvements in reputation, while TWC and BAC saw major declines. 2 Comments [Consumer, Tech]
- Wednesday, April 4, 2012, 10:02 AM FDA approval for the expanded use of Johnson & Johnson's (JNJ -0.5%) Intelence antiretroviral drug will improve the company's position in the evolving anti-infectives market. The approval provides JNJ with a drug that caters to the needs of young children and adolescents suffering from HIV. Comment! [Healthcare]
- Monday, March 26, 2012, 10:05 AM Johnson & Johnson (JNJ) plans to seek FDA approval in Q2 to use its Xarelto treatment for preventing lung clots after a large-scale Phase III study showed that the drug is as effective as and safer than standard treatments, which include Warfarin. Lung clots affect 600K Americans a year and kill up to 100K. (PR) 2 Comments [Healthcare]
-
- View all 0 replies
-
- View all 5 replies
-
-
O. Young Kwon: @ tashe. Thanks. Please make my number to a three digit, will you? Have a good summer. yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/16/2012, Monday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: 2 = 2-month term. Momentum can help you (a) to manage your portfolios piecemeal, not on-off fashion,<c>
-
O. Young Kwon: and (b) to decide what securities (ETFs and Stocks) to buy, sell, or hold. yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/13/2012, Friday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/12/2012, Thursday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/11/2012, Wednesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 3 replies
-
-
-
Skyler Greene
PG, UPS, JNJ, KO, CVX have higher dividends than bond yields. Fun. http://bit.ly/OrRAJ9 - View all 0 replies
-
The Wall Street Transcript
Bottom-Up Portfolio Construction with Anchors, Growth & Shorts; Money Manager Discusses $AAPL, $GOOG, $IBM, $JNJ - http://su.pr/1sRm6r - View all 0 replies
LATEST REPLIES
-
- View all 4 replies
-
R2k: thanks, yk. I suspect it's not too hard once the terms & abbreviations are fully understood. Will email you if I encounter problems. Thanks! -
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. Read my Instablog, "How To Use TMs.", "Go TANER: The Market Perimer.", "Income Portfolio", and "The Tiger Rule"yk
-
- View all 2 replies
-
O. Young Kwon: TMs are TANER Momentums. Read my Instablog, "How To Use TMs.", "Go TANER: The Market Perimer.", "Income Portfolio", and "The Tiger Rule"yk
-
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. read my Instablog, "How To Use TMs.", "Go TANER: The Market Perimer.", "Income Portfolio", and "The Tiger Rule"yk
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. Read my Instablog, "How To Use TMs.", "Go TANER: The Market Perimer.", "Income Portfolio", and "The Tiger Rule"yk
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 2 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
O. Young Kwon: x oil-field. If interested, "The Tiger Rule: TANER APP (I)" , "Income Portfolio: TANER APP (II),".yk
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 1 replies
-
Alan Brochstein: My LT target on SYNO is 28 assuming they aren't acquired soon (in which case they might fetch 22). Almost $6 per share in cash...
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 3 replies
-
-
Regarded Solutions: its out there.....click on my name and see my articles...."follow" me for more updates!
-
- View all 1 replies
-
O. Young Kwon: TMs are TANER Momentums. For details, please read my Instablog, "How To Use TMs." and "Go TANER: The Market Perimer." yk
-
- View all 4 replies
-
1ras1: the time of individual stock picking is upon us, the index is unhealthy in my point of view -